<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01539850</url>
  </required_header>
  <id_info>
    <org_study_id>CS-006</org_study_id>
    <nct_id>NCT01539850</nct_id>
  </id_info>
  <brief_title>Safety Evaluation of the LGL102 in Obese Subjects Treated With OMS102</brief_title>
  <official_title>Safety Evaluation of the LGL102 in Obese Subjects Treated With OMS102. A Prospective Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IntraPace, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IntraPace, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to evaluate the LGL102 implant safety in obese to&#xD;
      morbidly obese subjects treated with OMS102 system. The effect of the therapy on body weight&#xD;
      changes will be also evaluated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Transgastric sensor site healing</measure>
    <time_frame>3 months</time_frame>
    <description>Food sensor transgastric site healing will be evaluated during a gastro endoscopy exam performed three months after implant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Excess weight loss</measure>
    <time_frame>3, 6, and 12 months</time_frame>
    <description>Percentage of excess body weight loss (%EWL) compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Evaluation</measure>
    <time_frame>3, 6, and 12 months</time_frame>
    <description>Occurrence and severity of all adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>3, 6 and 12 months</time_frame>
    <description>Evaluation of the quality of life using the Moorehead-Ardelt II questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eating Behavior</measure>
    <time_frame>3, 6 and 12 months</time_frame>
    <description>Eating behavior (cognitive restraint, uncontrolled eating, and emotional eating) using the Three Factor Eating Questionnaire (TFEQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comorbid Conditions</measure>
    <time_frame>3, 6 and 12 months</time_frame>
    <description>Any reduction of blood pressure and oral diabetes medications</description>
  </secondary_outcome>
  <enrollment type="Actual">34</enrollment>
  <condition>Obesity</condition>
  <condition>Morbid Obesity</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OMS102</intervention_name>
    <description>Subjects will receive implanted OMS102 System.</description>
    <other_name>abiliti System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age of 18 - 60 years old at time of screening&#xD;
&#xD;
          -  BMI of 35 to 55 at time of screening&#xD;
&#xD;
          -  History of obesity ≥ 5 years&#xD;
&#xD;
          -  The subject has been under routine care of the investigator or another single&#xD;
             physician that can supply a medical record for at least 6 months prior to enrollment&#xD;
&#xD;
          -  Women with childbearing potential (i.e., not post-menopausal or surgically sterilized)&#xD;
             must agree to use adequate birth control methods&#xD;
&#xD;
          -  No significant weight loss (&lt; 5%) within four months prior to enrollment as documented&#xD;
             in the subject's medical record.&#xD;
&#xD;
          -  Successful psychological evaluation following the institution psychological evaluation&#xD;
             protocol for bariatric surgery or successful historic assessment performed no more&#xD;
             than 6 months prior to enrollment.&#xD;
&#xD;
          -  Glycosylated Hemoglobin; HbA1c ≤ 7.0 % at Visit 2 or historic value performed no more&#xD;
             than 3 months prior to enrollment.&#xD;
&#xD;
          -  If taking anti-depressant medications, they must be stable for at least six months&#xD;
             prior to enrollment&#xD;
&#xD;
          -  Willingness to refrain from using prescription, over the counter or herbal weight loss&#xD;
             products for the duration of the trial&#xD;
&#xD;
          -  Alert, mentally competent, and able to understand and willing to comply with the&#xD;
             requirements of the clinical trial, and personally motivated to abide by the&#xD;
             requirements and restrictions of the clinical trial&#xD;
&#xD;
          -  Able to provide voluntary informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any prior bariatric surgery&#xD;
&#xD;
          -  Other implanted electrical stimulation devices (e.g. pacemaker, defibrillator,&#xD;
             neurostimulator)&#xD;
&#xD;
          -  Diagnosed with past or current psychiatric condition that may impair his/her ability&#xD;
             to comply with the study procedures&#xD;
&#xD;
          -  Use of anti-psychotic medications&#xD;
&#xD;
          -  Diagnosed with a eating disorder such as bulimia or binge eating&#xD;
&#xD;
          -  Obesity due to an endocrinopathy (e.g. Cushing disease)&#xD;
&#xD;
          -  Insulin therapy&#xD;
&#xD;
          -  GI disease such as hiatal hernia (&gt; 5cm), gastroparesis, esophageal motility disorders&#xD;
             or intractable constipation.&#xD;
&#xD;
          -  Any history of peptic ulcer disease within 5 years prior to enrollment&#xD;
&#xD;
          -  History of Barrett's esophagus&#xD;
&#xD;
          -  Women who are pregnant, lactating or anticipate becoming pregnant within 24 months&#xD;
&#xD;
          -  Arthritis or other pathologies limiting physical activities that physician feels&#xD;
             should exclude the patient from the study.&#xD;
&#xD;
          -  Cardiac history that physician feels should exclude the patient from the study.&#xD;
&#xD;
          -  Use of another investigational device or agent in the 30 days prior to enrollment&#xD;
&#xD;
          -  A history of life-threatening disease within 5 years prior to enrollment&#xD;
&#xD;
          -  Any other condition that, in the opinion of the investigator, would make the subject&#xD;
             unsuitable for the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Horbach, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stadtkrankenhaus Schwabach</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wolfart Klinik</name>
      <address>
        <city>Graefelfing</city>
        <zip>92166</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stadtkrankenhaus Schwabach</name>
      <address>
        <city>Schwabach</city>
        <zip>91126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chirurgische Klinik und Poliklinik I Zentrum für Operative Medizin</name>
      <address>
        <city>Würzburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <study_first_submitted>February 22, 2012</study_first_submitted>
  <study_first_submitted_qc>February 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 28, 2012</study_first_posted>
  <last_update_submitted>February 27, 2012</last_update_submitted>
  <last_update_submitted_qc>February 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>obesity</keyword>
  <keyword>gastric stimulation</keyword>
  <keyword>morbid obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

